Sign In
Buy RGRX
$0.0006
+0 (+0%)
At Close: Jun 03, 2026
RegeneRx Effects Reverse Stock Split and Terminates SEC Reporting Obligations
08:00am, Tuesday, 15'th Aug 2023
ROCKVILLE, Md. , Aug. 15, 2023 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) ("RegeneRx" or the "Company"), a clinical-stage drug development company focused on tissue protection, rep
RegeneRx Receives Stockholder Approval for Reverse Stock Split
04:06pm, Monday, 07'th Aug 2023
ROCKVILLE, Md. , Aug. 7, 2023 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) ("RegeneRx" or the "Company"), a clinical-stage drug development company focused on tissue protection, repa
RegeneRx To Extend Consent Solicitation Vote
12:34pm, Tuesday, 01'st Aug 2023
ROCKVILLE, Md. , Aug. 1, 2023 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) ("RegeneRx" or "Company"), a clinical-stage drug development company focused on tissue protection, repair, a
RegeneRx Biopharmaceuticals (OTCMKTS:RGRX) Shares Down 3.4%
07:00pm, Wednesday, 24'th Nov 2021 Transcript Daily
Shares of RegeneRx Biopharmaceuticals, Inc. (OTCMKTS:RGRX) were down 3.4% on Monday . The company traded as low as $0.16 and last traded at $0.16. Approximately 62,440 shares traded hands during mid-day trading, a decline of 47% from the average daily volume of 117,240 shares. The stock had previously closed at $0.17. The stock has a […]
Market Snapshot A recently published report by QY Research, titled Global Systemic Inflammatory Response Syndrome Treatment Market Size, Status and Forecast 2022 gives an overview of the overall Systemic Inflammatory Response Syndrome Treatment market. This section sheds light on key
ROCKVILLE, Md., Oct. 6, 2021 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regenera
RegeneRx Issues Letter To Stockholders
08:30am, Thursday, 22'nd Jul 2021
ROCKVILLE, Md., July 22, 2021 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, re
RegeneRx JV Updates RGN-259 Regulatory Progress for Dry Eye Syndrome
08:07am, Wednesday, 14'th Jul 2021
ROCKVILLE, Md., July 14, 2021 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regenera
RegeneRx Biopharmaceuticals, Inc. Closes $2 Million Private Placement
01:00pm, Thursday, 01'st Jul 2021
ROCKVILLE, Md., July 1, 2021 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regenera
RegeneRx Biopharmaceuticals, Inc. Announces $2 Million Private Placement
04:15pm, Monday, 28'th Jun 2021
ROCKVILLE, Md., June 28, 2021 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regener
RegeneRx Joint Venture Reports Positive Results from ARISE-3 Clinical Trial Using RGN-259 to Treat Dry Eye Syndrome
08:30am, Friday, 14'th May 2021
ROCKVILLE, Md., May 14, 2021 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regenerat
RegeneRx Reports Topline Results of ARISE-3 Dry Eye Trial
06:51am, Thursday, 18'th Mar 2021
ROCKVILLE, Md., March 18, 2021 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage biopharmaceutical company focused on tissue protection,
RegeneRx JV Locks Clinical Trial Database for Phase 3 Dry Eye Trial
08:22am, Wednesday, 24'th Feb 2021
ROCKVILLE, Md., Feb. 24, 2021 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage biopharmaceutical company focused on tissue protection, re
RegeneRx Comments on ARISE-3 Clinical Trial
10:46am, Tuesday, 26'th Jan 2021
ROCKVILLE, Md., Jan. 26, 2021 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, rep
